DNMT3A and Alzheimer disease: The dCas9-Dnmt3a treatment also led to the alteration of APP methylation in mouse brain with minimal off-target effects; this result suggests the potential of dCas9-Dnmt3a-mediated APP hypermethylation for AD treatment.